PriceTargets.com logo

Talaris Therapeutics - TALS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.60 As of 01/14/2025 01:00 AM ET
▼ -0.87 (-4.47%)
Get New Talaris Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TALS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TALS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Talaris Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.60.

This chart shows the closing price for TALS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Talaris Therapeutics. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/15/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/17/2023HC WainwrightDowngradeBuy ➝ Neutral
2/23/2023Morgan StanleyLower TargetEqual Weight$6.00 ➝ $3.00
1/30/2023HC WainwrightReiterated RatingBuy$12.00
10/20/2022HC WainwrightInitiated CoverageBuy$18.00
9/9/2022Morgan StanleyLower TargetEqual Weight$8.00 ➝ $6.00
8/15/2022Evercore ISIBoost Target$20.00
7/5/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$20.00 ➝ $8.00
6/30/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$21.00 ➝ $7.00
5/24/2022Morgan StanleyLower TargetOverweight$21.00 ➝ $20.00
5/16/2022GuggenheimLower TargetNA$23.00
3/23/2022Morgan StanleyBoost TargetOverweight$20.00 ➝ $21.00
11/12/2021Leerink PartnersBoost TargetOutperform$21.00 ➝ $22.00
11/7/2021Evercore ISIReiterated RatingBuy$35.00
8/17/2021Evercore ISIReiterated RatingBuy$35.00
6/1/2021Leerink PartnersInitiated CoverageOutperform$21.00
6/1/2021Evercore ISIInitiated CoverageOutperform$35.00
6/1/2021GuggenheimInitiated CoverageBuy$26.00
6/1/2021Morgan StanleyInitiated CoverageOverweight$35.00
(Data available from 1/15/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Talaris Therapeutics logo
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
Read More

Today's Range

Now: $18.60
Low: $18.54
High: $20.08

50 Day Range

MA: $18.84
Low: $12.36
High: $28.36

52 Week Range

Now: $18.60
Low: $0.89
High: $27.95

Volume

264,479 shs

Average Volume

386,531 shs

Market Capitalization

$795.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Talaris Therapeutics?

The following equities research analysts have issued research reports on Talaris Therapeutics in the last twelve months:
View the latest analyst ratings for TALS.

What is the current price target for Talaris Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Talaris Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Talaris Therapeutics in the next year.
View the latest price targets for TALS.

What is the current consensus analyst rating for Talaris Therapeutics?

Talaris Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TALS.

What other companies compete with Talaris Therapeutics?

Other companies that are similar to Talaris Therapeutics include Immunovant, CRISPR Therapeutics, Vericel, Denali Therapeutics and SpringWorks Therapeutics. Learn More about companies similar to Talaris Therapeutics.

How do I contact Talaris Therapeutics' investor relations team?

The company's listed phone number is 502-398-9250. The official website for Talaris Therapeutics is talaristx.com. Learn More about contacing Talaris Therapeutics investor relations.